Home ›
Breast Cancer Trials ›
NCT07299825
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Trial Details
NCT ID NCT07299825
Phase PHASE2
Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status RECRUITING
Cancer Type Breast Cancer
Interventions
Locations (sample)
Key Eligibility Criteria
Male or female patient ≥ 18 years and ≤ 75 years when signing the informed consent form. Breast cancer patients by histopathology and/or cytology documented. In the advanced or metastatic stage, having received no more than 5 lines of systemic therapy, one of which must include a HER2 ADC with a topoisom… Patients must have experienced disease progression or intolerance during or after the most recent treatment prior to randomization.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →